Fortress Biotech Q3 net revenue rises, driven by dermatology sales
Overview
US biopharma firm's Q3 net revenue rose 9% yr/yr to $19.2 mln
Company posted Q3 net loss of $8.25 mln, reversing a profit last year
Fortress repaid $15 mln credit facility, leaving no parent-level debt
Outlook
Company did not provide specific financial guidance for future periods in its press release
Result Drivers
DERMATOLOGY SALES - Co said higher net revenue was mainly driven by increased sales of marketed dermatology products through Journey Medical
EMROSI PRESCRIPTIONS - Journey Medical reported approximately 40,000 Emrosi prescriptions in Q3, supported by improved reimbursement mix
ROYALTY INCOME - Co cited growing royalty income from ZYCUBO and UNLOXCYT as contributing to results
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Net Loss | $8.25 mln | ||
Q3 Income from Operations | -$7.19 mln |
Analyst Coverage
The one available analyst rating on the shares is "buy"
Wall Street's median 12-month price target for Fortress Biotech Inc is $5.00, about 151.3% above its November 12 closing price of $1.99
Reuters Recommended Reads
Nov 12 - Journey Medical's Q3 revenue rises on Emrosi demand but misses estimates
Nov 12 - EyePoint Pharmaceuticals Q3 revenue falls, net loss widens
Nov 12 - Rocket Pharmaceuticals Q3 net loss narrows as R&D costs fall
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)